New Paradigm Biosciences

Founded in 2019 and based in Acton, Massachusetts, New Paradigm Biosciences is a private, pre-clinical stage biotech focused on the intersection of AI/machine learning and drug discovery within immuno-oncology. The company's central innovation is a humanized mouse platform designed to overcome a major limitation in immunotherapy development: the poor predictive power of traditional animal models for human immune responses. By engrafting human tumors and immune cells into mice, NPB aims to discover and validate therapeutic antibodies against human-exclusive pathways, potentially unlocking new classes of more effective and targeted cancer treatments.

Proprietary humanized mouse platform engrafted with human immune systems and solid tumors to enable in vivo discovery and validation of therapeutic antibodies targeting human-exclusive immune pathways.

NPB competes with other biotechs developing humanized mouse models (e.g., The Jackson Laboratory, Taconic, Champions Oncology) and companies pursuing human-specific immunology targets. Its differentiation lies in the integrated application of its platform specifically for solid tumor immunotherapy discovery, potentially combined with AI/ML.